Pediatric Oncology Subcmte. Should Discuss Timing Of Studies – Workshop

The Pediatric Oncology Subcommittee should determine when it is appropriate to initiate clinical testing of oncologic agents in children, participants at an FDA workshop on pediatric oncology drug development agreed